NCT03941340

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib Mesylate (AST2818) in Chinese Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Allist Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose\[14C\] AST2818 in Chinese Healthy Male Volunteers

Detailed description

A Phase I Mass Balance and Biotransformation Study of Orally Administered \[14C\]-Alflutinib Mesylate (AST2818) in Chinese Healthy Male Volunteers

Conditions

• Healthy Male Volunteers

Interventions

Type	Name	Description
DRUG	[14]-AST2818	Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1

Timeline

• Start date: 2019-04-08
• Primary completion: 2019-09-06
• Completion: 2019-09-06
• First posted: 2019-05-07
• Last updated: 2020-01-06

Locations

1 site across 1 country: China